819 Capital Partners has acquired a significant minority stake in RiverD International to support the company's growth in the high-tech healthcare sector.

Information on the Target

RiverD International is a pioneering high-tech company based in the Netherlands, specializing in the development and manufacture of advanced instruments for non-invasive molecular analysis of human skin and tissue, utilizing Raman spectroscopy. This cutting-edge technology allows for real-time, reagentless measurements of skin tissue composition, positioning RiverD as a leader in the field. In addition to their core technology, RiverD is also focusing on the development of Raman-guided surgical techniques leveraging fiber-optic technologies, which promise to enhance surgical precision and outcomes.

The company serves a wide array of global markets, providing solutions essential for medical and dermatological research, as well as for research and development in the cosmetic and pharmaceutical industries. With a strong emphasis on innovation, RiverD's contributions to these sectors underscore its commitment to advancing health technologies.

Industry Overview

The healthcare technology industry in the Netherlands is characterized by its strong emphasis on innovation and research. The country's strategic investments in health tech have fostered an environment that culti